Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten maintains an Outperform rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) and raises the price target from $30 to $34.
July 23, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten maintains an Outperform rating on Kiniksa Pharmaceuticals and raises the price target from $30 to $34.
The raised price target and maintained Outperform rating from a reputable analyst at Wedbush is likely to boost investor confidence in Kiniksa Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100